{"disease":{"id":"breast-cancer-early-breast-cancer","name":"breast cancer early breast cancer"},"drugs":{"marketed":[{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of breast cancer in postmenopausal women with hormone receptor-positive early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":57,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05952557","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5500,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07521397","title":"Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.","phase":"","overall_status":"COMPLETED","enrollment_count":5358,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05774951","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":4300,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07030231","title":"Use of Intraoperative Radiotherapy in Breast Cancer","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Parc de Salut Mar","has_results":false},{"nct_id":"NCT07153757","title":"De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":2934,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06637202","title":"Swebcg 91:A RT. Breast Conserving Surgery With or Without Radiotherapy for Breast Cancer Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1187,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT06728527","title":"PARTial BREast RECONstruction With Chest Wall Perforator Flap","phase":"","overall_status":"RECRUITING","enrollment_count":1001,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT07379918","title":"Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05113251","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":927,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05386719","title":"Cardiometabolic Screening Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT06970912","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":393,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04109391","title":"Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"Tanvex BioPharma USA, Inc.","has_results":true},{"nct_id":"NCT06995118","title":"The Application of \"HUAXI Hole 1\" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction","phase":"NA","overall_status":"RECRUITING","enrollment_count":337,"lead_sponsor_name":"Du Zhenggui","has_results":false},{"nct_id":"NCT07331506","title":"Validation of the Oncoliq Test for the Early Detection of Breast Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Oncoliq US Inc","has_results":false},{"nct_id":"NCT06035016","title":"Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06834204","title":"Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":266,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT07317778","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":249,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04829643","title":"Axillary Staging in Early Breast Cancer: SNB vs PET/MRI","phase":"NA","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06791018","title":"Cancer Exercise: Evaluation of a Mobile App in Breast Cancer Survivors","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT06409221","title":"VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Concr","has_results":false},{"nct_id":"NCT07273357","title":"Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Region Jönköping County","has_results":false},{"nct_id":"NCT07269691","title":"RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":194,"lead_sponsor_name":"Pengfei Qiu","has_results":false},{"nct_id":"NCT06768931","title":"Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":192,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07421141","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":186,"lead_sponsor_name":"National Medical Research Radiological Centre of the Ministry of Health of Russia","has_results":false},{"nct_id":"NCT06927180","title":"SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06781996","title":"A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT07404462","title":"Correlation Between Tumor-infiltrating Lymphocytes and Response to Systemic Therapy in Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"Institute of Oncology Ljubljana","has_results":false},{"nct_id":"NCT04294225","title":"Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT06144944","title":"Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07366112","title":"CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":158,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06823414","title":"Endoscopy/Robotic Assisted Nipple Skin Sparing Mastectomy","phase":"","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Alejandra García-Novoa","has_results":false},{"nct_id":"NCT06943911","title":"Reflects the Intervention (AI Chatbot)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Mostafa Shaban","has_results":false},{"nct_id":"NCT07071402","title":"A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT06890221","title":"Impact of PErioperative Nutrition Intervention on Bioimpedance Phase Angle (IPENIPA) In Breast Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":114,"lead_sponsor_name":"University of Malaya","has_results":false},{"nct_id":"NCT06676761","title":"Outcomes of a Novel Technique Minimal Scar Mastectomy","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"KK Women's and Children's Hospital","has_results":false},{"nct_id":"NCT06800612","title":"Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06650748","title":"Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT02605915","title":"Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06806072","title":"BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":96,"lead_sponsor_name":"Parc de Salut Mar","has_results":false},{"nct_id":"NCT04595435","title":"IORT-Breast at Medical Center Navicent Health","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT06807502","title":"Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device","phase":"NA","overall_status":"RECRUITING","enrollment_count":93,"lead_sponsor_name":"ScreenCell","has_results":false},{"nct_id":"NCT06001762","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06902051","title":"Study on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07042568","title":"The Effect of Education Given on Preventing Mouth Ulcers in Women With Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Trakya University","has_results":false},{"nct_id":"NCT05318274","title":"Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Coordinación de Investigación en Salud, Mexico","has_results":false},{"nct_id":"NCT07022509","title":"Matrix Rotation Flap Versus Single Incision Lateral Sulcus Mammoplasty","phase":"NA","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Batterjee Medical College","has_results":false},{"nct_id":"NCT07071038","title":"Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT07398118","title":"CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":61,"lead_sponsor_name":"St. Antonius Hospital","has_results":false},{"nct_id":"NCT06949046","title":"Effects of a Nursing-led Communication Using Mobile Health Information in Breast Cancer Patients Undergoing Concurrent Chemotherapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT07013422","title":"The Effectiveness of Psychoeducational Intervention in Reducing Anxiety, Depression, and Symptom Burden Among Omani Women Diagnosed With Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Sultan Qaboos Comprehensive Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}